Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Life Sciences, deals, pharmaceuticals

Sirtris Gains SIRT3 Licenses from Harvard

Ryan McBride 9/16/08

Sirtris announced today that it has gained two exclusive licenses to Harvard University patents related to SIRT3, an enzyme believed to protect against cellular damage. The Cambridge, MA, biotech firm—which was acquired by British drug giant GlaxoSmithKline (NYSE: GSK) in June for $720 million—says the licenses cover assays that may identify SIRT3 activators for diseases of aging.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.